Incidence Rates of Adverse Events (CTCAE Severity ≥3) During HER2-Directed Breast Cancer Treatment Assessing the Impact of App-Based Electronic Patient-Reported Outcomes in the Randomized Controlled PRO2 Trial.
Trojan A, van Mackelenbergh M, Brucker C, Forstbauer H, Thiel M, Kolberg HC, Welslau M, Kreiss-Sender J, Dröse S, Roth S, Raeth P, Vetter M, Blum D, Fasching PA
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.